Researchers monitoring the brain activity of a patient with a severe binge-eating problem reported that Eli Lilly's GLP-1 ...

Eli Lilly's next-gen obesity drugs, led by oral orforglipron and triple-acting retatrutide, aim to reshape the fast-growing ...

The two drugmakers swiftly denied any affiliation with Mangoceuticals, who claimed it had partnered with them.

In a remarkable turn of events within the pharmaceutical industry, Eli Lilly's tirzepatide has overtaken Merck's Keytruda to become the world’s best-selling medicine. This shift highlights not only ...

Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Merck, which has claimed ...

Novo Nordisk A/S (NYSE:NVO) on Sunday presented data from the STEER real-world study of evidence gathered from actual patient experiences at the European Society of Cardiology (ESC) Congress 2025. The ...

The White House today announced landmark drug pricing agreements with Eli Lilly and Company and Novo Nordisk to lower the ...

Eli Lilly LLY reported 54% revenue growth in the third quarter as its diabetes and obesity drug tirzepatide (Mounjaro/Zepbound) continued to gain share globally, and management raised top- and ...

Eli Lilly and Novo Nordisk have become the latest pharma giants to strike price-reduction deals with the White House, agreeing to sell their weight loss drugs at cut-rate prices to patients in the U.S ...

Lilly has submitted the results from SURPASS-PEDS to global regulatory agencies for an expanded indication. About tirzepatide Tirzepatide is a once-weekly GIP (glucose-dependent insulinotropic ...

Investing in pharmaceutical companies with diversified revenue bases and strong R&D pipelines could be a lucrative strategy.